“Efficacy and Safety of up to Two Years of Tralokinumab Treatment in Adults of Different Racial Subgroups With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s144, https://doi.org/10.25251/skin.7.supp.144.